Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.00121359223300968 -0.0194174757281554
Stock impact report

Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial

Aldeyra Therapeutics, Inc. (ALDX) 
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aldeyra.com/investor-relations
Company Research Source: PR Newswire
LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed dosing in the ALLEVIATE Phase 3 clinical trial of topical ocular reproxalap in patients with allergic conjunctivitis."We look forward to announcing the results of the ALLEVIATE clinical trial in early 2019 as the first of three Phase 3 readouts expected next year," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Affecting approximately 20% of the population worldwide, allergic conjunctivitis is a common disease that can cause persistently disturbing symptoms, and is often associated with dry eye disease. Reproxalap's novel mechanism has the potential to be uniquely effective in allergic conjunctivitis, and may offer increased durability of activity relative to standard of care." Show less Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ALDX alerts

from News Quantified
Opt-in for
ALDX alerts

from News Quantified